Softwr

Healthcare · head to head

Lunit vs Sysmex

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
Sysmex logo

Sysmex

Healthcare

Haematology and urinalysis analysers sold with the middleware that decides which results a scientist ever sees

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; Sysmex the middleware is not realistically separable from the instrument contract, so a laboratory that likes Caresphere but wants another vendor analyser has no clean path to buying just the software.
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, Sysmex covers Caresphere autovalidation.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and Sysmex actually diverge.

Attributes where Lunit and Sysmex differ
AttributeLunitSysmex
PlatformsWebWeb, Windows, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in Sysmex

  • Caresphere autovalidation
  • Delta and moving average QC
  • WAM rule sets
  • Fleet telemetry
  • Reagent inventory tracking
  • Extended white cell parameters
  • LIS interfacing
  • Multi-site harmonisation

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Sysmex
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Sysmex
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Sysmex
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Sysmex

Sysmex

  • A hospital network standardising full blood count reporting across six laboratories so a result released at a district hospital carries the same rules as the tertiary centrenot Lunit
  • A pathology group trying to raise autovalidation rates to absorb rising demand without recruiting more biomedical scientistsnot Lunit
  • A blood sciences service consolidating haematology, coagulation and urinalysis onto one middleware layer to remove three separate QC workflowsnot Lunit
  • A laboratory running 24 hour service that needs remote analyser telemetry so an overnight fault is triaged before the morning shift arrivesnot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Sysmex

  • The middleware is not realistically separable from the instrument contract, so a laboratory that likes Caresphere but wants another vendor analyser has no clean path to buying just the software.
  • Reagent rental agreements set a minimum annual test volume, and a laboratory whose activity falls after a service reconfiguration keeps paying against a floor it no longer reaches.
  • Regulatory clearance is granted per parameter and per region, so a flag or extended parameter that a European laboratory relies on may not be released for clinical use on the same analyser in the United States.
  • Interfacing to a non-Sysmex laboratory information system is a project, not a configuration step, and integration effort is often quoted separately from the instrument contract.
  • Autovalidation rule sets are configured locally, so the gains depend entirely on whether the laboratory has the clinical governance capacity to write, validate and audit those rules; buying the software does not deliver the saving on its own.

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Sysmex

On request
  • Reagent rental or cost per reportable result contract$undefined/year
    • Analyser hardware, reagents, service and Caresphere middleware bundled into a price per test
    • Five to seven year term typical
    • Minimum annual test volume commitment

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose Sysmex if

  • You need caresphere autovalidation.
  • You work on Web, Windows, On-premise.
  • You also want delta and moving average qc.
Sysmex review

Questions people ask

Is Lunit or Sysmex better?
Neither clearly leads. Lunit starts at On request and Sysmex at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or Sysmex?
Lunit starts at On request and Sysmex at On request.
Does Lunit or Sysmex run on more platforms?
Lunit runs on Web. Sysmex runs on Web, Windows, On-premise.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what Sysmex is typically brought in for.
What can Lunit do that Sysmex cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. Sysmex covers Caresphere autovalidation, Delta and moving average QC, WAM rule sets, Fleet telemetry.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Sysmex: Can I buy Caresphere without Sysmex analysers?

Not in practice. It is licensed as part of the instrument and reagent agreement, and its value depends on Sysmex-specific parameters and flags.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Sysmex: Is Sysmex software FDA cleared?

Clearance attaches to the analysers and to individual reported parameters, not to the middleware as a whole. Check the specific parameter and the specific market, because clearances differ between the United States, Europe and Japan.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Sysmex: How is it priced?

Per reportable result, or as a reagent rental with a minimum annual volume. There is no per user or per seat price.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Sysmex: What is the contract length?

Typically five to seven years, aligned to instrument depreciation, with reagent pricing fixed or indexed over the term.

Share

Related pages

More on Lunit

More on Sysmex

Keep looking

Other head to heads